Search

Your search keyword '"N Di Muzio"' showing total 407 results

Search Constraints

Start Over You searched for: Author "N Di Muzio" Remove constraint Author: "N Di Muzio"
407 results on '"N Di Muzio"'

Search Results

101. Comparison of self-reported acute urinary incontinence in patients treated with adjuvant or salvage post-prostatectomy intensity modulated-radiotherapy (IMRT)

102. Application of failure mode and effect analysis to tomotherapy treatment delivery

103. 63. Quantification of skin dose changes during Tomotherapy for head-neck cancer by dose-of-the-day recalculation

105. 237. Robustness of FDG-PET radiomic features against tumor delineation in two clinical relevant scenarios

106. Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: a multi-institutional analysis

108. EP-1191: Outcomes of a mono-institutional experience of IG-IMRT in Glioblastoma

109. EP-1990: Skin DVHs predict cutaneous toxicity in Head and Neck cancer patients treated with Tomotherapy

110. PO-0976: Rectal cancer radiochemotherapy: pathological response predicted by modeling early tumor regression

111. PO-0825: Urinary calprotectin as a promising biomarker of RT-induced urinary toxicity. Preliminary results

112. Factors affecting self-reported, long-term (1-2 yrs) urinary incontinence from postprostatectomy RT

113. The prognostic role of early PSA response after salvage radiation therapy: Long-term results from a multi-institutional study

114. What is the optimal field of post-prostatectomy radiation therapy? Long-term results from a multi-institutional study

115. Assessing the impact and predictors of other-cause mortality in patients treated with post-prostatectomy salvage radiation therapy in order to avoid possible overtreatment: Results from a large, multi-institutional study

116. EP-1459 Impact of sentinel lymph-node biopsy and FDG-PET in staging and radiation treatment of anal cancer

118. OC-0611 Planned and delivered DVHs of the skin predict acute cutaneous toxicity after IGRT for HN cancer

119. Validation of a method for 'dose of the day' calculation in head-neck tomotherapy by using planning ct-to-MVCT deformable image registration

120. Urinary calprotectin as a promising bio-marker of radiation-induced urinary toxicity and worsening of urinary function. Preliminary results

121. EP-1315: Prostate cancer lymph nodal disease: SBRT only or extensive prophylactic irradiation and boost?

122. PO-0730: The independent benefit deriving from high doses and WPRT in salvage post-prostatectomy radiotherapy

123. PO-0694: Post-operative Intensity-Modulated hypofractionated Image-Guided Radiotherapy in cholangiocarcinoma

124. EP-1319: 'Adjuvant'/ radical radiotherapy in prostate cancer patients with synchronous bone oligometastasis

125. EP-1318: Is hypofractionation combined to WPRT effective in high risk prostate cancer patients?

127. PO-0852: External validation of a TCP model predicting PSA relapse after post-prostatectomy Radiotherapy

128. External validation of a TCP model predicting PSA relapse after post-prostatectomy radiotherapy

129. An automatic contour propagation method to follow parotid gland deformation during head-and-neck cancer tomotherapy

130. 26. Stepping validation of 'knowledge-based' models for semi-automatic plan optimization: The case of concomitant treatment of pelvic nodes and prostatic bed in post-prostatectomy radiotherapy

131. 88. Integration of MR-tractography into radiation treatment planning for high-grade glioma

132. EP-1449: Neoadjuvant chemoradiotherapy IG-IMRT PET based in esophageal or esophageal gastric junction cancer

133. EP-1221: Hypoxia imaging with 18F-FAZA PET/CT in Radiotherapy Planning for High Grade Gliomas

134. EP-1390: Salvage (postponed) hypofractionated tomotherapy for progressive MPM in patients with intact lungs

135. Assessing the need for and the optimal duration of hormonal therapy in association with post-prostatectomy radiation therapy: Results from a multi-institutional study

136. Quality indicators in the intensity modulated/image-guided radiotherapy era

137. EP-1157 FDG-PET guided dose escalation with TomoTherapy for locally advanced oropharyngeal cancer

138. PD-0530: Predictors of hematological toxicity after whole-pelvis intensity-modulated post-prostatectomy radiotherapy

139. EP-1627: Inter-observer variability of intestinal loops delineation after whole pelvis radiotherapy for prostate patients

140. PO-1087 Gastrointestinal toxicity in post-prostatectomy pelvis irradiation: intestinal loops and sigmoid colon contouring

141. PO-0749: Factors predicting late severe urinary incontinence after postprostatectomy RT: a longitudinal study

142. EP-1347: Could 'radical' RT be a reasonable choice in bone oligometastatic prostate cancer patients?

143. EP-1300: Preoperative, Adaptive Radiotherapy with Tomotherapy concomitant with chemotherapy in rectal cancer

144. PO-0721: Impact of sentinel lymph-node biopsy on staging and treatment in patients with anal cancer

145. EP-1349: Long term results of a phase I-II study of moderate hypofractionated IGRT in prostate cancer

146. PO-0651: Five year outcome and soft tissue toxicity of breast cancer hypofractionated adjuvant radiotherapy

147. EP-1159: Hypofractionated adjuvant radiotherapy and concomitant trastuzumab for breast cancer: 5-year results

148. EP-1671: Calculation of the skin dose-of- the-day during Tomotherapy for head and neck cancer patients

149. OC-0222: GnRH receptor blockade reduces radiation-induced bladder toxicity: first evidence in a rat model

Catalog

Books, media, physical & digital resources